Hematology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Search results for "Panobinostat"

The results from PANORAMA-1 ( PANobinostat ORAl in Multiple MyelomA ) trial were presented at ASCO meeting, showing a 37% improvement in progression-free survival ( PFS ) when using the investigationa ...

In 2013 American Society of Hematology ( ASH ) Annual Meeting data on several compounds in development for the treatment of multiple myeloma were presented. Alternating vs sequential regimens I ...

The FDA ( Food and Drug Administration ) has approved Farydak ( Panobinostat, previously known as LBH589 ) capsules in combination with Bortezomib ( Velcade ) and Dexamethasone for the treatment of pa ...